Phase 4
Completed N=165
Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular
Source: ClinicalTrials.gov NCT02242201 ↗Enrolled (actual)
165
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcomePrimary: Maximum Postoperative Pain Score — 3.0; 4.0; 3.0 units on a scale — p=0.033
◆ Published Evidence
Established
61citations · ~7 / year
Continuous Posterior Lumbar Plexus Nerve Block Versus Periarticular Injection with Ropivacaine or Liposomal Bupivacaine for Total Hip Arthroplasty: A Three-Arm Randomized Clinical Trial.
Summary
Total hip arthroplasty is a one of the most commonly performed surgical procedures with increasing numbers anticipated over the next several decades. The purpose of this study was to find a better way to make patients comfortable after their hip surgery. Three different ways of providing pain relief were compared, a peripheral nerve block in the lower back outside of the spinal space (using bupivacaine, a numbing medicine), or injections around the hip joint with one of two different medicines, either Ropivacaine or Liposomal Bupivacaine (Exparel®).
Linked Publications
-
Continuous Posterior Lumbar Plexus Nerve Block Versus Periarticular Injection with Ropivacaine or Liposomal Bupivacaine for Total Hip Arthroplasty: A Three-Arm Randomized Clinical Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Postoperative Pain Score |
3.0; 4.0; 3.0 | 0.033 sig |
| SECONDARY Total Opioid Consumption During Hospitalization |
15; 15; 15; 10; 10; 10 | 0.948 |
Eligibility Criteria
Inclusion Criteria
- Adult patients with an American Society of Anesthesiologists (ASA) physiological status I-III
- Patients presenting for unilateral primary total hip arthroplasty
- Patients 18 years of age and older
Exclusion Criteria
- Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome
- History of long term use of daily opioids (>1 months) with Oral Morphine Equivalent (OME) >5mg/day
- Body mass index (BMI) > 40 kg/m2
- Allergies to medications used in this study such as: fentanyl,hydromorphone, ketorolac, ibuprofen, acetaminophen, local anesthetics, oxycodone, tramadol, ondansetron, droperidol, dexamethasone, celecoxib and OxyContin
- Major systemic medical problems such as:
- severe renal disorder defined as glomerular filtration rate (GFR) 1.5], refusal, etc.).
- Previous contralateral hip replacement managed with regional or periarticular injection
- Unable to follow-up at the 3 month interval at Mayo Clinic in Rochester, Minnesota
- Pregnancy or breastfeeding (women of child-bearing potential will require a negative pregnancy test)
Data sourced from ClinicalTrials.gov (NCT02242201) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.